好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

APOE Gene Promoter Polymorphisms as Determinant of Middle-Age Ischemic Stroke in a Belgiam Population
Cerebrovascular Disease and Interventional Neurology
(-)
005
Authors/Disclosures
Sherine Abboud, MD, PhD (Cabinet Abboud) No disclosure on file
Paul Mehta Paul Mehta has nothing to disclose.
Samir Alkabie, MD, MSc Dr. Alkabie has nothing to disclose.
Kwo Wei David Ho, MD, PhD (Nerve and Pain Institute LLC) No disclosure on file
Serge A. Blecic, MD, PhD (Neuroblecic) No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Patrice Laloux, MD No disclosure on file
No disclosure on file
Sandrine Jeangette No disclosure on file
Philippe Desfontaines, MD (CHC-Clinique MontLegia) No disclosure on file
Jean Jacquy No disclosure on file
No disclosure on file
No disclosure on file
Massimo Pandolfo, MD, FAAN (Montreal Neurological Institute/Hospital) Dr. Pandolfo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Design Therapeutics . Dr. Pandolfo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Pandolfo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Solid Bio. Dr. Pandolfo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. Pandolfo has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Design Therapeutics. Dr. Pandolfo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Larimar. Dr. Pandolfo has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Genetics. Dr. Pandolfo has stock in Voyager Therapeutics. The institution of Dr. Pandolfo has received research support from Freidreich Ataxaia Research Alliance. Dr. Pandolfo has a non-compensated relationship as a Scientific Advisory Board with Friedreich Ataxia Research Alliance that is relevant to AAN interests or activities. Dr. Pandolfo has a non-compensated relationship as a Member-Meeting Management Committee with AAN that is relevant to AAN interests or activities.